知镜 Cognispect · 医学文献与研究工作台

Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology.

Izzi M, Shtembari K, Specchiarello S, Calandrelli C, Mancini S, Mela MM, Rossi V, Giorgione R, Rossini D, Pillozzi S, Antonuzzo L, Roviello G.
Future oncology (London, England) · 2026-10-03 · PMID 42828418

文献摘要

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting presented important advances in genitourinary oncology. During a resident-led Post-ASCO GU 2026 meeting supervised by genitourinary oncology experts, clinically relevant studies were selected and critically discussed. This report reviews PROTEUS and TALAPRO-3 in prostate cancer; RAMPART and the KEYNOTE-564 circulating tumor DNA analysis in renal cell carcinoma; and POTOMAC, EV-302/KEYNOTE-A39, EV-303, and NEXUS-01 in urothelial carcinoma. These studies highlight the growing roles of perioperative systemic therapy, biomarker-guided treatment, antibody-drug conjugates, and patient-reported outcomes. Their clinical implications vary according to study design and evidence maturity: some reinforce established standards, whereas others support potential future strategies or remain hypothesis-generating. Although its educational impact was not formally assessed, the initiative provided a structured setting for discussing and critically appraising emerging congress evidence.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。